Paul Dent Selected Research

Cyclin-Dependent Kinases (cdk Proteins)

12/2007	Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
2/2007	Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
1/2007	Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
8/2006	The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
2/2006	Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.
11/2005	Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
10/2004	Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
10/2004	The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.
7/2004	Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
4/2003	The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Dent Research Topics

Disease

185	Neoplasms (Cancer) 01/2022 - 07/2002
60	Melanoma (Melanoma, Malignant) 01/2022 - 07/2002
50	Leukemia 01/2016 - 01/2002
38	Carcinoma (Carcinomatosis) 01/2019 - 03/2002
21	Breast Neoplasms (Breast Cancer) 01/2022 - 07/2002
21	Mitochondrial Diseases (Mitochondrial Disease) 01/2020 - 01/2002
19	Glioma (Gliomas) 01/2020 - 02/2003
18	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 06/2002
18	Prostatic Neoplasms (Prostate Cancer) 01/2016 - 11/2003
16	Infections 10/2015 - 07/2002
15	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 07/2003
14	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2005
11	Multiple Myeloma 08/2012 - 11/2002
9	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 11/2005
9	Brain Neoplasms (Brain Tumor) 01/2016 - 02/2003
8	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2005
8	Colonic Neoplasms (Colon Cancer) 01/2022 - 09/2007
7	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 07/2003
7	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 11/2003
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2008 - 07/2004
6	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2019 - 04/2003
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2012 - 11/2005
6	Myeloid Leukemia (Leukemia, Myelocytic) 12/2010 - 01/2002
5	Kidney Neoplasms (Kidney Cancer) 01/2022 - 05/2009
5	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 05/2014
5	Lung Neoplasms (Lung Cancer) 01/2019 - 01/2008
5	Carcinogenesis 09/2013 - 05/2003
4	Multiple Sclerosis 01/2020 - 01/2014
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 06/2008

Drug/Important Bio-Agent (IBA)

68	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2002
48	Histone Deacetylase InhibitorsIBA 01/2022 - 05/2003
46	Phosphotransferases (Kinase)IBA 01/2022 - 01/2002
41	InterleukinsIBA 02/2015 - 08/2003
39	CytokinesIBA 10/2017 - 02/2003
34	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 10/2005
32	Pharmaceutical PreparationsIBA 01/2022 - 06/2005
21	Drug CombinationsIBA 01/2021 - 11/2005
21	Vorinostat FDA Link 01/2020 - 12/2003
21	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2016 - 12/2003
18	neratinibIBA 01/2022 - 10/2017
17	7-hydroxystaurosporine (UCN 01)IBA 05/2013 - 05/2002
14	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 11/2003
14	CeramidesIBA 07/2012 - 03/2005
14	Imatinib Mesylate (Gleevec)FDA Link 08/2008 - 01/2002
13	Sildenafil Citrate (Viagra)FDA Link 01/2019 - 10/2010
13	CaspasesIBA 06/2008 - 03/2002
12	Beclin-1IBA 11/2020 - 07/2009
12	Proteasome InhibitorsIBA 01/2014 - 11/2003
12	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA 04/2012 - 01/2002
12	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2012 - 11/2002
12	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2007 - 09/2002
11	Valproic Acid (Depakote)FDA LinkGeneric 01/2020 - 08/2009
10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 07/2002
10	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 07/2003
10	Pemetrexed (MTA)FDA Link 01/2019 - 07/2011
10	Lapatinib (GW572016)FDA Link 06/2016 - 11/2009
10	alvocidib (flavopiridol)IBA 08/2012 - 03/2002
9	Caspase 9IBA 01/2019 - 05/2002
9	Messenger RNA (mRNA)IBA 02/2015 - 07/2002
9	Small Interfering RNA (siRNA)IBA 01/2015 - 08/2004
9	Cytochromes c (Cytochrome c)IBA 07/2007 - 01/2002
8	Death Domain ReceptorsIBA 01/2022 - 05/2010
8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 11/2007
8	regorafenibIBA 01/2021 - 10/2013
8	Endoplasmic Reticulum Chaperone BiPIBA 10/2016 - 03/2010
8	obatoclaxIBA 10/2013 - 11/2009
8	Bortezomib (Velcade)FDA Link 04/2013 - 11/2003
8	Interleukin-10 (Interleukin 10)IBA 05/2012 - 05/2004
7	OSU 03012IBA 08/2015 - 08/2006
7	AD 5IBA 01/2014 - 06/2010
7	tanespimycin (17AAG)IBA 03/2011 - 09/2003
7	Caspase 3 (Caspase-3)IBA 10/2010 - 01/2002
6	entinostat (MS 275)IBA 01/2021 - 07/2005
6	CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)IBA 01/2020 - 09/2008
6	pazopanib FDA Link 01/2019 - 05/2014
6	AfatinibIBA 01/2019 - 04/2016
6	Phosphodiesterase 5 InhibitorsIBA 01/2019 - 03/2014
6	Protein Kinase CIBA 01/2015 - 10/2002
6	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 08/2012 - 01/2002
6	adenovirus receptorIBA 01/2011 - 07/2003
6	NF-kappa B (NF-kB)IBA 03/2010 - 04/2004
6	Butyric Acid (Butanoic Acid)IBA 01/2006 - 09/2003
5	Dimethyl FumarateIBA 01/2020 - 01/2014
5	LigandsIBA 12/2019 - 04/2003
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 05/2003
5	AntibodiesIBA 01/2019 - 09/2017
5	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 09/2015 - 10/2010
5	Heat-Shock Proteins (Heat-Shock Protein)IBA 05/2010 - 09/2003
5	Mitogen-Activated Protein KinasesIBA 05/2010 - 01/2002
5	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 05/2010 - 01/2002
5	Mitogen-Activated Protein Kinase 3IBA 11/2009 - 02/2005
5	U 0126 (UO 126)IBA 11/2009 - 11/2002
4	Fingolimod Hydrochloride (FTY720)FDA Link 01/2020 - 01/2014
4	carfilzomibIBA 06/2019 - 06/2010
4	Protein Kinases (Protein Kinase)IBA 01/2019 - 04/2003
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2013

Therapy/Procedure

69	Therapeutics 01/2021 - 02/2003
20	Drug Therapy (Chemotherapy) 01/2020 - 06/2002
7	Radiotherapy 01/2020 - 07/2003
6	Immunotherapy 01/2020 - 09/2017